Gregory M. Weinhoff Sells 11,742 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Gregory M. Weinhoff sold 11,742 shares of the business’s stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $16.47, for a total transaction of $193,390.74. Following the completion of the sale, the insider now directly owns 159,782 shares of the company’s stock, valued at $2,631,609.54. The trade was a 6.85 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Centessa Pharmaceuticals Stock Up 2.2 %

Shares of Centessa Pharmaceuticals stock opened at $16.96 on Thursday. The stock has a market capitalization of $2.24 billion, a price-to-earnings ratio of -11.08 and a beta of 1.53. Centessa Pharmaceuticals plc has a twelve month low of $7.38 and a twelve month high of $18.97. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The business’s 50 day simple moving average is $16.80 and its 200-day simple moving average is $15.03.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.05. Equities research analysts forecast that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Analyst Upgrades and Downgrades

CNTA has been the subject of several research analyst reports. TD Cowen started coverage on Centessa Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating for the company. Guggenheim upped their price target on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Friday, November 15th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, Centessa Pharmaceuticals has an average rating of “Buy” and a consensus target price of $25.83.

Institutional Trading of Centessa Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Jane Street Group LLC acquired a new stake in shares of Centessa Pharmaceuticals in the third quarter valued at approximately $2,834,000. Wellington Management Group LLP acquired a new stake in Centessa Pharmaceuticals in the 3rd quarter valued at approximately $1,609,000. Nantahala Capital Management LLC bought a new stake in Centessa Pharmaceuticals during the 2nd quarter valued at $4,064,000. State Street Corp acquired a new position in Centessa Pharmaceuticals during the 3rd quarter worth $777,000. Finally, Ally Bridge Group NY LLC bought a new position in shares of Centessa Pharmaceuticals in the third quarter worth $4,951,000. 82.01% of the stock is currently owned by institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.